Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). (Q43991572)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

title

Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Alan V. Boddy

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

author name string

M A Batey

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

J G Wright

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

D R Newell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

M J Lind

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

A H Calvert

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

publication date

1 May 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

8 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

volume

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

1081-1089

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

Prediction of carboplatin clearance from standard morphological and biological patient characteristics

8 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Variability in the pharmacokinetics of epirubicin: a population analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Dose-response effect of adjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Relationship between fluorouracil systemic exposure and tumor response and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Metabolism of oxazaphosphorines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Determination of methotrexate in serum by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Estimation of glomerular filtration rate in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

Dose and time dependencies of 5-fluorouracil pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900024-2

7 January 2021

10.1016/S0959-8049(02)00024-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12008196%20AND%20SRC:MED&resulttype=core&format=json

release_tb3sg3biubfmnpzpusklxln4yq

8 November 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tb3sg3biubfmnpzpusklxln4yq

24 November 2022

mapped directly with Wikidata item

1 reference